PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 6, 2026Journal of Medical Case Reports0 citationsOpen Access

Effectiveness of neoadjuvant chemotherapy with lenvatinib plus pembrolizumab in advanced endometrial cancer: a case report

KKKatsuyuki KonnaiHFHiroyuki FujiwaraTNTsuguto Notomi

Key Points

  • This research investigates the effectiveness of lenvatinib and pembrolizumab as neoadjuvant therapy in advanced endometrial cancer.
  • Administered neoadjuvant chemotherapy using lenvatinib and pembrolizumab
  • Monitored tumor size and surgical outcomes
  • Assessed pathological response post-surgery
  • Achieved significant tumor regression prior to surgery
  • Enabled complete surgical resection of tumors
  • Resulted in a pathological complete response in the report case

Abstract

Lenvatinib plus pembrolizumab may represent a feasible neoadjuvant option for achieving tumor regression and enabling surgical resection with a pathological complete response in advanced endometrial cancer.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Konnai et al. (2026) studied this question.

synapsesocial.com/papers/69aa6f3c531e4c4a9ff595a8https://doi.org/10.1186/s13256-026-05920-4
Ask AI
Helpful
Bookmark
Share
View Full Paper